Clinical trials for hidradenitis suppurativa
Explore current HS research studies, learn what questions to ask, and find opportunities that may be a fit for you or your family.
Featured HS clinical trials
These studies are highlighted to make it easier for patients and caregivers to review opportunities in plain language. Always confirm details directly with the study team.
Clinical Trials for Teens
Now enrolling: Hidradenitis Suppurativa (HS) Research Study for Teens
For ages 12–17 with severe HS affecting multiple body areas, diagnosed for at least 6 months. Evaluating a topical investigational drug. No placebo — all participants receive the study active treatment.
More InfoClinical study for HS patients
Hidradenitis Suppurativa causes painful symptoms. You can help yourself and others with our clinical study.
- Test our active investigational ingredient
- Supervision by specialised staff
- Study participants wanted!
The study is recruiting for the following countries:
More InfoWhat is a clinical trial?
Clinical trials are research studies that help doctors and researchers learn more about conditions like HS, test potential treatments, and understand how care can improve over time.
Learn
Review the study purpose, age range, location, visits, and what participation involves.
Screen
The study team asks questions to see whether you may meet the study requirements.
Decide
You can ask questions, review risks and benefits, and choose whether participation feels right.
Participate
If eligible, you follow the study plan with guidance from the research team.
Clinical trials are a choice.
Being interested in a trial does not mean you have to enroll. Asking questions is part of the process. You should feel informed, respected, and supported before making any decision.
U.S. clinical trial opportunities
Browse HS clinical trials currently listed for U.S. participants. These are pulled from your Clinical Trial posts using the U.S. location filter.
A Study to Assess the Concentration of Bimekizumab in Mature Breast Milk From Mothers Receiving Treatment With Bimzelx® (Bimekizumab) (BE CARING)
AGE: 18+
ALL
Status: Recruiting
A Long-Term Follow-Up Observational Study to Evaluate Safety in Subjects Who Have Received a Gene-Modified Regulatory T Cell (Treg) Therapeutic
AGE: 18+
ALL
Status: Recruiting
Radiotherapy for Refractory Hidradenitis Suppurativa (RADIANTSUPPoRT)
AGE: 18+
II or III
Status: Recruiting
A Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of Subcutaneous Sonelokimab in Participants With Moderate to Severe Hidradenitis Suppurativa
AGE: 18+
Moderate to Severe
Status: Recruiting
Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib (STOP-LTR)
AGE: 18+
ALL
Status: Recruiting
SKIN Disease Profiling by an Exploratory, pRospective, Biomarker Study in dermatoloGY Practice (SKINERGY)
AGE: 18+
Moderate to Severe
Status: Recruiting
A Real World Study to Globally Assess Disease Burden in Adolescent and Adult Participants With Alopecia Areata, Vitiligo, or Hidradenitis Suppurativa
AGE: 12+
Moderate to Severe
Status: Recruiting
A Long-Term Follow-Up Observational Study to Evaluate Safety in Subjects Who Have Received a Gene-Modified Regulatory T Cell (Treg) Therapeutic
AGE: 18+
ALL
Status: Recruiting
Evaluate Safety and Pharmacokinetics of INF904 in Subjects With Moderate to Severe Chronic Spontaneous Urticaria or Hidradenitis Suppurativa
AGE: 18+
Moderate to Severe
Status: Recruiting
Tibulizumab Skin Healing and Inflammation Evaluation for Lasting Defense (TibuSHIELD)
AGE: 18+
II & III
Status: Recruiting
A Study Evaluating BFB759 in Moderate to Severe Hidradenitis Suppurativa
AGE: 18+
Moderate to Severe
Status: Recruiting
An Open-label, Single-arm Study to Evaluate Pharmacokinetics and Safety of Subcutaneous Sonelokimab in Adolescents With Moderate to Severe Hidradenitis Suppurativa (VELA-TEEN)
AGE: 12 -17
Moderate to Severe
Status: Recruiting
An Open-label, Time-lagged, Dose-escalation Study to Evalaute the Safety and Efficacy of Subcutaneous Siplizumab in the Treatment of Hidradenitis Suppurativa.
AGE: 18+
Moderate to Severe
Status: Recruiting
A 16-Week Study to Learn About the Study Medicine Called Ritlecitinib in Adults With Long Lasting Painful Red Skin Lumps, Known by the Medical Term, Hidradenitis Suppurativa, or HS.
AGE: 18+
Moderate to Severe
Status: Recruiting
A Study for Evaluating Safety & Efficacy of Topical Roflumilast 0.3% Foam in Hidradenitis Suppurativa
AGE: 18+
All
Status: Recruiting
Efficacy, Safety, and Tolerability of HB0043 in Hidradenitis Suppurativa Patients.
AGE: 18+
Moderate to Severe
Status: Recruiting
Brivekimig for the Treatment of Moderate to Severe Hidradenitis Suppurativa
AGE: 18+
Moderate to Severe
Status: Recruiting
Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa (TRuE-HS2)
AGE: 12+
I & II
Status: Recruiting
Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa (TRuE-HS1)
AGE: 12+
I & II
Status: Recruiting
A Study to Assess the Pharmacokinetics and Safety of Bimekizumab in Children and Adolescents With Moderate to Severe Hidradenitis Suppurativa
AGE: 9 to 17
Moderate to Severe
Status: Recruiting
Study to Evaluate the Maximal Use of Ruxolitinib Cream in Adult and Adolescent Participants With Hidradenitis Suppurativa
AGE: 12+
I, II, III
Status: Recruiting
Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult Patients With Moderate to Severe Hidradenitis Suppurativa
AGE: 12+
Moderate to Severe
Status: Recruiting
A Study to Assess Molecular Changes in Adult Participants With Moderate to Severe Hidradenitis Suppurativa or With Moderate to Severe Atopic Dermatitis Receiving Subcutaneous Injections of Lutikizumab
AGE: 18-75
SEVERITY: Moderate to severe
Status: Recruiting
A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult Patients With Moderate to Severe Hidradenitis Suppurativa (RECHARGE 1)
AGE: AGE: 18+
SEVERITY: Moderate to severe
Status: Recruiting
A Study of the Efficacy and Safety of Brensocatib in Adults With Moderate to Severe Hidradenitis Suppurativa (HS) (CEDAR)
AGE: AGE: 18-80
SEVERITY: Moderate or severe
Status: Recruiting
Participants with Mild to Moderate Hidradenitis Suppurativa Will Receive EVO101 a Topical Cream 0.1%
AGE: AGE: 18+
SEVERITY: Mild to moderate
Status: Recruiting
Study to Evaluate the Efficacy and Safety of Subcutaneous Sonelokimab Compared With Placebo in Adult Participants With Moderate to Severe Hidradenitis Suppurativa
AGE: AGE: 18+
HURLEY STAGE: II & III
Status: CURRENTLY RECRUITING
Topical Ruxolitinib 1.5% for Hidradenitis Suppurativa Treatment
AGE: AGE: 12+
HURLEY STAGE: I & II
Status: CURRENTLY RECRUITING
A Study to Evaluate the Efficacy and Safety of AVTX-009 in Patients with Moderate to Severe Hidradenitis Suppurativa
AGE: AGE: 18+
HURLEY STAGE: II & III
Status: CURRENTLY RECRUITING
Myriad™ Augmented Soft Tissue Reconstruction Registry
AGE: AGE: 18+
HURLEY STAGE: All
Status: CURRENTLY RECRUITING
Regulation of Inflammatory Genes in Hidradenitis Suppurativa
AGE: AGE: 18+
HURLEY STAGE: All
Status: CURRENTLY RECRUITING
Botulinum Toxin Therapy in Hidradenitis Suppurativa
AGE: AGE: 18+
HURLEY STAGE: All
Status: CURRENTLY RECRUITING
The Living With a Long-Term Condition Study
AGE: AGE: 18+
HURLEY STAGE: All
Status: CURRENTLY RECRUITING
Clinical and Biological Characteristics of Hidradenitis Suppurativa
AGE: AGE: 13+
HURLEY STAGE: All
Status: CURRENTLY RECRUITING
Study to Collect in a Real-world populatIon Data on the Treatment Pattern of Secukinumab in Adult Patients With Moderate to Severe Hidradenitis Suppurativa (HS) in Routine Clinical Practice in the Russian Federation
AGE: AGE: 18+
SEVERITY: Moderate to Severe
Status: CURRENTLY RECRUITING
A Study to Evaluate the Efficacy and Safety of Subcutaneous Sonelokimab Compared With Placebo in Adult Participants With Moderate to Severe Hidradenitis Suppurativa
AGE: AGE: 18+
HURLEY STAGE: II & III
Status: CURRENTLY RECRUITING
Study of Single Doses of SBT777101 in Subjects With Hidradenitis Suppurativa
AGE: AGE: 18-70
HURLEY STAGE: II & III
Status: CURRENTLY RECRUITING
Capsule Microbiota Transplant Therapy for Hidradenitis Suppurativa
AGE: AGE: 18+
HURLEY STAGE: All
Status: CURRENTLY RECRUITING
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy
AGE: AGE: 12+
HURLEY STAGE: II & III
Status: CURRENTLY RECRUITING
A Study of Eltrekibart (LY3041658) in Adult Participants With Moderate to Severe Hidradenitis Suppurativa
AGE: AGE: 18-70
HURLEY STAGE: II & III
Status: CURRENTLY RECRUITING
A Phase 2 Study to Evaluate the Efficacy and Safety of SAR444656 Compared With Placebo in Adult Participants With Moderate to Severe Hidradenitis Suppurativa
AGE: AGE: 18-70
HURLEY STAGE: II & III
Status: CURRENTLY RECRUITING
Tissue Repository Providing Annotated Biospecimens for Approved Investigator-directed Biomedical Research Initiatives
AGE: AGE: 18+
HURLEY STAGE: All
Status: CURRENTLY RECRUITING
Long Term Observational Study to Collect in a Real-world populatIon Data on the Treatment Pattern of secukinumAb in Adult Patients With Moderate to Severe Hidradenitis Suppurativa.
AGE: AGE: 18+
SEVERITY: Moderate to Severe
Status: CURRENTLY RECRUITING
Patient’s Perspective on the Evolution of Hidradenitis Suppurativa Burden After Secukinumab Initiation
AGE: AGE: 18+
HURLEY STAGE: All
Status: CURRENTLY RECRUITING
Battlefield Acupuncture for Pain in Hidradenitis Suppurativa
AGE: AGE: 18+
HURLEY STAGE: All
Status: CURRENTLY RECRUITING
The Evaluation of Injection Site Pain and Adherence in Patients Switching From a Low To High Concentration Adalimumab (AVT-02) Across Multiple Indications.
AGE: AGE: 18+
HURLEY STAGE: All
Status: CURRENTLY RECRUITING
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa
AGE: AGES: 16+
HURLEY STAGE: II & III
Status: CURRENTLY RECRUITING
The Ohio State University Dermatology Biorepository
AGE: AGE: 7+
HURLEY STAGE: All
Status: CURRENTLY RECRUITING
International clinical trial opportunities
Explore currently listed HS clinical trials taking place outside the United States. New international studies are added as opportunities become available.
SKIN Disease Profiling by an Exploratory, pRospective, Biomarker Study in dermatoloGY Practice (SKINERGY) (SKINERGY)
AGE: 18+
Moderate to Severe
Status: Recruiting
Collection of Samples From Subjects With Various Skin Conditions and Healthy Volunteers
AGE: 18+
ALL
Status: Recruiting
A Study to Assess the Concentration of Bimekizumab in Mature Breast Milk From Mothers Receiving Treatment With Bimzelx® (Bimekizumab) (BE CARING)
AGE: 18+
ALL
Status: Recruiting
A Phase I Study of QLS12010 Capsules: Safety, Tolerability, PK, PD, and Food Effects in Healthy Adults and Moderate to Severe Atopic Dermatitis Patients
AGE: 18+
Moderate to Severe
Status: Recruiting
A Real World Study to Globally Assess Disease Burden in Adolescent and Adult Participants With Alopecia Areata, Vitiligo, or Hidradenitis Suppurativa (MEASUREAAVitHS)
AGE: 12+
Moderate to Severe
Status: Recruiting
A Single and Multiple Ascending Dose Trial of LT-002-158 Tablets in Healthy Adult Volunteers
AGE: 18+
ALL
Status: Recruiting
Long Term Observational Study to Collect in a Real-world populatIon Data on the Treatment Pattern of Secukinumab in Adult Patients With Moderate to Severe HS Within the Italian Population
AGE: 18+
Moderate to Severe
Status: Recruiting
Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib (STOP-LTR)
AGE: 18+
ALL
Status: Recruiting
SKIN Disease Profiling by an Exploratory, pRospective, Biomarker Study in dermatoloGY Practice (SKINERGY)
AGE: 18+
Moderate to Severe
Status: Recruiting
A Real World Study to Globally Assess Disease Burden in Adolescent and Adult Participants With Alopecia Areata, Vitiligo, or Hidradenitis Suppurativa
AGE: 12+
Moderate to Severe
Status: Recruiting
Evaluate Safety and Pharmacokinetics of INF904 in Subjects With Moderate to Severe Chronic Spontaneous Urticaria or Hidradenitis Suppurativa
AGE: 18+
Moderate to Severe
Status: Recruiting
Tibulizumab Skin Healing and Inflammation Evaluation for Lasting Defense (TibuSHIELD)
AGE: 18+
II & III
Status: Recruiting
Efficacy, Safety, and Tolerability of HB0043 in Hidradenitis Suppurativa Patients.
AGE: 18+
Moderate to Severe
Status: Recruiting
Brivekimig for the Treatment of Moderate to Severe Hidradenitis Suppurativa
AGE: 18+
Moderate to Severe
Status: Recruiting
Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa (TRuE-HS2)
AGE: 12+
I & II
Status: Recruiting
Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa (TRuE-HS1)
AGE: 12+
I & II
Status: Recruiting
A Study to Assess the Pharmacokinetics and Safety of Bimekizumab in Children and Adolescents With Moderate to Severe Hidradenitis Suppurativa
AGE: 9 to 17
Moderate to Severe
Status: Recruiting
Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult Patients With Moderate to Severe Hidradenitis Suppurativa
AGE: 12+
Moderate to Severe
Status: Recruiting
A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult Patients With Moderate to Severe Hidradenitis Suppurativa (RECHARGE 1)
AGE: AGE: 18+
SEVERITY: Moderate to severe
Status: Recruiting
Study to Collect in a Real-world populatIon Data on the Treatment Pattern of Secukinumab in Adult Patients With Moderate to Severe Hidradenitis Suppurativa (HS) in Routine Clinical Practice in the Russian Federation
AGE: AGE: 18+
SEVERITY: Moderate to Severe
Status: CURRENTLY RECRUITING
The Living With a Long-Term Condition Study
AGE: AGE: 18+
HURLEY STAGE: All
Status: CURRENTLY RECRUITING
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy
AGE: AGE: 12+
HURLEY STAGE: II & III
Status: CURRENTLY RECRUITING
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa
AGE: AGES: 16+
HURLEY STAGE: II & III
Status: CURRENTLY RECRUITING
The Evaluation of Injection Site Pain and Adherence in Patients Switching From a Low To High Concentration Adalimumab (AVT-02) Across Multiple Indications.
AGE: AGE: 18+
HURLEY STAGE: All
Status: CURRENTLY RECRUITING
Patient’s Perspective on the Evolution of Hidradenitis Suppurativa Burden After Secukinumab Initiation
AGE: AGE: 18+
HURLEY STAGE: All
Status: CURRENTLY RECRUITING
Long Term Observational Study to Collect in a Real-world populatIon Data on the Treatment Pattern of secukinumAb in Adult Patients With Moderate to Severe Hidradenitis Suppurativa.
AGE: AGE: 18+
SEVERITY: Moderate to Severe
Status: CURRENTLY RECRUITING
A Phase 2 Study to Evaluate the Efficacy and Safety of SAR444656 Compared With Placebo in Adult Participants With Moderate to Severe Hidradenitis Suppurativa
AGE: AGE: 18-70
HURLEY STAGE: II & III
Status: CURRENTLY RECRUITING
Placebo vs. Nocebo Effect
Learn the difference between the placebo and nocebo effects, how they influence HS clinical trials and treatment experiences, and why a positive mindset may help you get the most from your care.
Placebo vs. Nocebo Effect
Learn the difference between the placebo and nocebo effects, how they influence HS clinical trials and treatment experiences, and why a positive mindset may help you get the most from your care.
Questions to ask before joining a clinical trial
You deserve clear answers before deciding whether a study is right for you.
Study basics
What is the study testing? How long does it last? How many visits are required?
Eligibility
What age, diagnosis, severity, medication, or location requirements apply?
Costs and compensation
Are study visits, travel, parking, or time compensated? Are there any costs?
Risks and benefits
What are the possible side effects, risks, and expected monitoring steps?
Placebo or active treatment
Is there a placebo or vehicle group? Will everyone receive the study treatment?
Your rights
Can you stop participating? Who do you contact with concerns or questions?